Safety and economic analysis of selective histopathology following cholecystectomy: multicentre, prospective, cross-sectional FANCY study. Issue 4 (28th February 2022)

• Record Type: Journal Article
• Authors: Bastiaenen, Vivian P.; van Vliet, Jaap L. P.; de Savornin Lohman, Elise A. J.; Corten, Bartholomeus J. G. A.; de Jonge, Joske; Kraima, Anne C.; Swank, Hilko A.; van Acker, Gijs J. D.; van Geloven, Anna A. W.; in 't Hof, Klaas H.; Koens, Lianne; de Reuver, Philip R.; van Rossem, Charles C.; Slooter, Gerrit D.; Tanis, Pieter J.; Terpstra, Valeska; Dijkgraaf, Marcel G. W.; Bemelman, Willem A.
• Is Part Of: British journal of surgery. Volume 109:Issue 4(2022)
• Page Start: 355
• Page End: 362
• Publication Date: 2022-02-28
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znab469
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Background: There is ongoing debate concerning the necessity of routine histopathological examination following cholecystectomy. In order to reduce the pathology workload and save costs, a selective approach has been suggested, but evidence regarding its oncological safety is lacking. Methods: In this multicentre, prospective, cross-sectional study, all gallbladders removed for gallstone disease or cholecystitis were systematically examined by the surgeon for macroscopic abnormalities indicative of malignancy. Before sending all specimens to the pathologist, the surgeon judged whether histopathological examination was indicated. The main outcomes were the number of patients with hypothetically missed malignancy with clinical consequences (upper limit two-sided 95 per cent c.i. below 3:1000 considered oncologically safe) and potential cost savings of selective histopathological examination. Results: Twenty-two (2.19:1000) of 10 041 specimens exhibited malignancy with clinical consequences. In case of a selective policy, surgeons would have held back 7846 of 10041 (78.1 per cent) gallbladders from histopathological examination. Malignancy with clinical consequences would have been missed in seven of 7846 patients (0.89:1000, upper limit 95% c.i. 1.40:1000). No patient benefitted from the clinical consequences, while two were harmed (futile additional surgery). Of 15 patients in whom malignancy with clinical consequences would have been diagnosed, one benefitted (residual disease radically removed), two potentially benefitted (palliative systemic therapy), and four experienced harm (futile additional surgery). Estimated cost savings established by replacing routine for selective histopathological examination were €703 500 per 10 000 patients. Conclusion: Selective histopathological examination following cholecystectomy is oncologically safe and could reduce pathology workload, costs, and futile re-resections. Abstract : This Dutch multicentre, prospective, cross-sectional study including 10 041 patients who underwent a cholecystectomy for gallstone disease or cholecystitis provides robust evidence that selective histopathological examination of gallbladder specimens following the initial macroscopic assessment by the surgeon is oncologically safe and will likely result in substantial cost savings.